clinical implications of the revel trial in nsclc
Published 6 years ago • 147 plays • Length 4:14Download video MP4
Download video MP3
Similar videos
-
6:18
treating nsclc with ramucirumab: the revel trial
-
2:26
the phase 3 revel trial in nsclc
-
2:26
the revel study in lung cancer
-
3:09
key points from the revel trial in nsclc
-
6:53
nsclc: rapid progression data in the revel trial
-
4:16
ramucirumab data for lung cancer
-
6:02
ramucirumab in nsclc
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
2:37
exploratory analysis of frontline therapies in revel: phase 3 trial of ramucirumab in nsclc
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
2:35
exploratory analysis of frontline therapies in revel: a phase 3 trial of ramucirumab in nsclc
-
6:11
patient selection for ramucirumab in nsclc
-
3:25
use of ramucirumab for patients with squamous or nonsquamous lung cancer
-
1:00:44
practical application of recent clinical data for immunotherapy in nsclc
-
5:13
clinical trial for early-stage non-small cell lung cancer following surgery
-
1:46
dr. martin reck on docetaxel/ramucirumab in nsclc
-
2:11
dr. kim discusses data from the impower150 trial in nonsquamous nsclc
-
5:46
trials of ramucirumab in gastric cancer
-
1:06
phase iii real-world pacific-r trial for nsclc